Bristol-Myers Squibb Company Overview
Get informed when a big investor buys or sells
+ Follow13.82
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for BRM.DE is 13.82. That is below the Healthcare sector average of 70.94. Investors often review this figure alongside Bristol-Myers Squibb Company's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BRM.DE currently prints 13.82 for P/E ratio, while the sector average sits near 70.94. That is roughly 80.5% below the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb Company's growth, margins, and balance sheet.
A P/E ratio of 13.82 for Bristol-Myers Squibb Company is not 'good' or 'bad' on its own. Compare it with the peer average (70.94) and with BRM.DE's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting BRM.DE's P/E ratio (13.82), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb Company's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
